Navigation Links
Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States
Date:5/14/2013

PHILADELPHIA, May 14, 2013 /PRNewswire/ -- The IP & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced the release of a life sciences report, "An Outlook on U.S. Biosimilar Competition," providing a comprehensive view of the challenges facing companies entering the United States biosimilar drug market and key players predicted to break into this developing pharmaceutical space.

While the U.S. continues to take steps toward entering the global biosimilar market, it lags behind other nations in this space. The report compares U.S. and EU regulations to underscore the significant differences between these regions and explore ways the U.S. can compete more effectively, in addition to reviewing emerging regulatory developments in India and China. It also identifies potential leaders of the U.S. market, including Amgen, Hospira and Sandoz, among the top three pharmaceutical companies with the most potential to dominate the early stages of biosimilar medications entering the U.S.

Biologic medicines, including biosimilars, are developed using living organisms instead of synthesized chemical compounds and are known to effectively treat a range of conditions including rheumatoid arthritis, metastatic breast cancer, non-Hodgkin lymphoma and anemia. Innovative biologic treatments can cost tens of thousands of dollars per year. Competition from biosimilar therapies will help to lower the cost of these expensive treatments, thus helping to reduce healthcare costs and increase patient access.

"This report is a prime example of the insight that can be gleaned by our internal experts using our high quality, curated life sciences data," said Jon Brett-Harris , managing director, Thomson Reuters Life Sciences.  "Our goal is to provide cutting-edge information and solutions to support our clients making confident decisions related to drug discovery, development and delivery."

"An Outlook on U.S. Biosimilar Competition" was created by Thomson Reuters experts in generic drug and API intelligence. The team utilized Newport Premium, the industry's leading tool for identifying and evaluating generic drug development and licensing opportunities, to compile the report.

View "An Outlook on U.S. Biosimilar Competition."

Learn more about Thomson Reuters Generic and API Intelligence and Newport Premium.

Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minn., Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira dévoile sa stratégie appareil mondiale
2. Hospira enthüllt weltweite Gerätestrategie
3. Hospira revela estrategia global para sus dispositivos
4. Hospira revela estratégia global para dispositivos
5. Hospira Reports First-Quarter 2013 Results
6. Hospira Unveils Global Device Strategy
7. Hospira Names Matthew R. Stober Senior Vice President of Operations
8. Hospira to Host Conference Call for First-Quarter 2013 Results
9. Hospira Announces Executive Changes
10. Hospira Reports Fourth-Quarter and Full-Year 2012 Results
11. Hospira to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... 19, 2017 The Mobile X-Ray product segment is ... CAGR during the forecast period Mobile X-Ray segment ... digital mobile X-Ray devices market, which is estimated to be ... at a CAGR of 7% over the forecast period. Mobile ... more than US$ 100 Mn in 2017 over 2016. The ...
(Date:4/19/2017)... April 19, 2017 The Global Effective ... to 2022 report has covered and analysed the potential of ... on market size, shares and growth factors. The report identifies ... and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... April 27, 2017 , ... The ... Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis of how behavioral economics ... takeaways to apply immediately to IRR programs, the report highlights proven behavioral economics ...
(Date:4/27/2017)... ... April 27, 2017 , ... Last night, Christine Collins ... the Year for her extraordinary compassion and lifelong dedication to serve others. Since ... caregivers for the prestigious award each year – identifying a CAREGiver who has ...
(Date:4/27/2017)... ... , ... Are you investing in the safety of your friends and family? ... summer. While most of us assume this type of accident will never happen to ... are taking the time to learn how to respond effectively or prevent these accidents ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... Journal ... adults. It can have severe consequences to overall dental health, including complications with speech, ... often turn to dental implants to replace lost teeth. As the number of tooth ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, president and ... by Enterprising Women magazine as one of its 2017 Enterprising Women of the ... Winners have demonstrated that they have fast-growth businesses, mentor or actively support other ...
Breaking Medicine News(10 mins):